SAPCD2: A Potential Drug Target for Various Diseases (G89958)

Target Name: SAPCD2

NCBI ID: G89958

SAPCD2

SAPCD2: A Potential Drug Target for Various Diseases

SAPCD2 (S-Adenylate Binding Protein-C2 Subunit), also known as TS (Tissue Salt-Induced) and MDEP (Mesothelin-Induced), is a protein that is expressed in various tissues and cells in the human body. It is a member of the Salt-Induced Membrane Proteins (SIMPs) family, which includes proteins that are involved in various physiological processes, including cell signaling, inflammation, and tissue mechanics.

SAPCD2 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, liver, and pancreas. It is primarily localized to the cell membrane, where it plays a role in various cellular processes, including cell signaling, ion transport, and signaling pathways.

One of the unique features of SAPCD2 is its ability to interact with various types of molecules, including ion channels, receptors, and other proteins. This interactivity makes SAPCD2 an attractive drug target, as it can be used to modulate the activity of various cellular processes and to treat a variety of diseases.

SAPCD2 has been shown to be involved in a number of signaling pathways that are important for cellular processes, including cell signaling, ion transport, and cell adhesion. For example, studies have shown that SAPCD2 is involved in the regulation of ion channels, including the Potassium channels that are involved in muscle and nerve function.

Additionally, SAPCD2 has been shown to be involved in the regulation of cell adhesion and migration. This is important for the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

SAPCD2 has also been shown to play a role in the regulation of inflammation and immune responses. This is important for the development and progression of inflammatory diseases, including cancer and autoimmune diseases.

In addition to its role in cellular signaling and immune responses, SAPCD2 has also been shown to play a role in the regulation of tissue mechanics and cell migration. This is important for the development and progression of diseases that are characterized by the breakdown of tissue structure and the movement of cells into new areas of the body.

Given its involvement in a variety of cellular processes, SAPCD2 is an attractive drug target for a variety of diseases. For example, studies have shown that SAPCD2 can be used to treat a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, SAPCD2 has been shown to be involved in the regulation of cancer cell growth and metastasis, making it an attractive target for cancer treatments.

In conclusion, SAPCD2 is a protein that is expressed in various tissues and cells in the human body. It is a member of the SIMPs family and plays a role in various cellular processes, including cell signaling, ion transport, and signaling pathways. Its ability to interact with a variety of molecules makes SAPCD2 an attractive drug target for a variety of diseases. Further research is needed to fully understand the role of SAPCD2 in cellular processes and its potential as a drug target.

Protein Name: Suppressor APC Domain Containing 2

Functions: Plays a role in planar mitotic spindle orientation in retinal progenitor cells (RPCs) and promotes the production of symmetric terminal divisions (By similarity). Negatively regulates the mitotic apical cortex localization of GPSM2 (PubMed:26766442). Involved also in positive regulation of cell proliferation and tumor cell growth (PubMed:23576022, PubMed:23704824)

The "SAPCD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SAPCD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets